-
ALSO READ
Lupin receives USFDA approval for Colesevelam Hydrochloride Tablets
Cadila Health gets DCGI nod to initiate Phase-3 clinical trials for Covid-19 vaccine
Zydus Cadila to initiate phase III clinical trials for ZyCoV-D
Vivimed Labs soars after Jeedimetla facility gets Ukraine GMP approval
Glenmark Pharma gets USFDA nod for amphetamine sulfate tablets
-
Vivimed Labs rose 3.76% to Rs 17.95 after the company announced that it received approval for two products from Uzbekistan Government.
The company received approval for Bilastin tablets and Orzole combi. Both the products are manufactured at the company's Hyderabad-based facility that has been approved by PICS & Health Canada.Bilastin tablets (brand name Flustin) is a second-generation antihistamine used in treating allergic Rhino conjunctivitis and Urticaria (hives).
Orzole combi (Ofloxacin + Ornidazole) is used in treating bacterial and parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.
Ramesh Krishnamurthy, CEO of Vivimed Labs said: "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy."
Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.
On a consolidated basis, Vivimed Labs posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU